Semaglutide's thyroid tumor warning has stayed on the label since Ozempic's 2017 approval
Ozempic's thyroid warning dates to its first approval and still rules out some patients from semaglutide, even though the human risk remains unresolved.
Ozempic (semaglutide) reached the U.S. market on December 5, 2017, cleared for adults with type 2 diabetes, and it arrived with a boxed warning about thyroid C-cell tumors and a contraindication that rules out certain patients [1][2][3]. The label has been revised many times since, but that warning and that contraindication have not gone away. The DailyMed version updated June 1, 2026 still lists both [1].
The warning language is precise about what is and is not known. Semaglutide causes thyroid C-cell tumors in rodents, according to the label, and the label states that whether it does the same in humans is unknown because the human relevance of those rodent tumors has not been determined [1]. The contraindication covers anyone with a personal or family history of medullary thyroid carcinoma (MTC) and anyone with multiple endocrine neoplasia syndrome type 2 (MEN 2) [1]. Doctors are directed to counsel patients about the potential MTC risk and about symptoms of thyroid tumors; the highlights section does not spell out those symptoms [1]. A separate contraindication covers serious hypersensitivity to semaglutide or to ingredients in the pen [1].
Semaglutide is now sold under several brands. Rybelsus, a tablet for type 2 diabetes, was first approved September 20, 2019. Wegovy injection, for weight reduction, followed on June 4, 2021. Wegovy tablets were approved December 22, 2025, and the R2 oral formulation was rebranded as Ozempic tablets on January 30, 2026 [2].
Meanwhile the uses of the injectable have widened. Regulators added cardiovascular risk reduction on January 16, 2020, a 2 mg dose strength on March 28, 2022, and a kidney indication covering sustained eGFR decline, end-stage kidney disease and cardiovascular death on January 28, 2025 [2][3]. Other label additions include hypoglycemia and severe allergic reactions in April 2021, acute gallbladder disease in March 2022, birth defects and miscarriages in October 2022, ileus in September 2023, and pulmonary aspiration under general anesthesia or deep sedation in November 2024 [3]. The most recent major change shown on the current label, dated October 2025, addresses severe gastrointestinal adverse reactions [1]. The most frequently reported side effects, seen in at least 5 percent of patients, are nausea, vomiting, diarrhea, abdominal pain and constipation [1].
One point of disagreement: a regulatory roundup dates the Ozempic approval to December 5, 2016 [3]. DailyMed gives 2017 as the initial U.S. approval year [1], and Drugs.com records a December 5, 2017 approval with a December 5, 2016 filing [2].
Why it matters for patients
The thyroid contraindication acts as a filter in front of the prescription rather than a side effect people discover later. Anyone whose personal or family medical history includes MTC or MEN 2 appears on the label's exclusion list, and that has been true since the first approval [1][2]. Because the tumor signal comes from animals and the human question is unresolved, the label neither confirms nor dismisses a risk for people who take the drug [1]. It has not been reported whether the boxed-warning text is worded identically on Wegovy, Rybelsus, Ozempic tablets and the injectable [2]. The same labeling carries warnings about pancreatitis, diabetic retinopathy complications, hypoglycemia when combined with insulin or insulin secretagogues, kidney injury from dehydration, severe gastrointestinal reactions, serious allergic reactions, gallbladder disease and aspiration during sedation or anesthesia [1].
What happens next
No FDA move to remove or rewrite the thyroid C-cell tumor warning has been reported. Semaglutide labels have kept changing for other reasons, most recently over severe gastrointestinal reactions in October 2025 [1]. Two unrelated milestones carry dates: Medicare's BRIDGE program, described as limited access to weight-loss drugs ahead of expected full coverage in 2027, is set for July 2026, and the FDA approved Eli Lilly's oral orforglipron (Foundayo) for obesity on April 1, 2026 [3].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.